Failure to Predict Amikacin Elimination in Critically Ill Patients with Cancer Based on the Estimated Glomerular Filtration Rate: Applying PBPK Approach in a Therapeutic Drug Monitoring Study

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2023 May 31

PMID 37256410

Authors

Joao Paulo Telles

Mariana Suelotto Diegues

Karen Cristina Migotto

Olivia de Souza Borges

Rodrigo Reghini

Brenda Vianna Gavazza

Leonardo Pinto

Pedro Caruso

Ivan Leonardo Franca E Silva

Stephan Schmidt

Fernanda de Lima Moreira

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this work was to integrate the Therapeutic Drug Monitoring (TDM) with the model-informed precision dosing (MIPD) approach, using Physiologically-based Pharmacokinetic/Pharmacodynamic (PBPK/PD) modelling and simulation, to explore the relationship between amikacin exposure and estimated glomerular filtration rate (GFR) in critically ill patients with cancer.

Methods: In the TDM study, samples from 51 critically-ill patients with cancer treated with amikacin were analysed. Patients were stratified according to renal function based on GFR status. A full-body PBPK model with 12 organs model was developed using Simcyp V. 21, including steady-state volume of distribution of 0.21 L/kg and renal clearance of 6.9 L/h in healthy adults. PK parameters evaluated were within the 2-fold error range.

Results: During the validation step, predicted vs observed amikacin clearance values after single infusion dose in patients with normal renal function, mild and moderate renal impairment were 7.6 vs 8.1 L/h (7.5 mg/kg dose); 3.8 vs 4.5 L/h (1500 mg dose) and 2.2 vs 3.1 L/h (25 mg/kg dose), respectively. However, predicted vs observed amikacin clearance after a single dose infusion of 1400 mg in critically-ill patients with cancer were 1.46 vs 1.63 (P = 0.6406) L/h (severe), 2.83 vs 1.08 (P < 0.05) L/h (moderate), 4.23 vs 2.49 (P = 0.0625) L/h (mild) and 7.41 vs 3.36 (P < 0.05) L/h (normal renal function).

Conclusion: This study demonstrated that estimated GFR did not predict amikacin elimination in critically-ill patients with cancer. Further studies are necessary to find amikacin PK covariates to optimize the pharmacotherapy in this population. Therefore, TDM of amikacin is imperative in cancer patients.

References

Prayle A, Watson A, Fortnum H, Smyth A . Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 2010; 65(7):654-8. PMC: 2921289. DOI: 10.1136/thx.2009.131532. View

Pitta R, Gasparetto J, Moraes T, Telles J, Tuon F . Antimicrobial therapy with aminoglycoside or meropenem in the intensive care unit for hospital associated infections and risk factors for acute kidney injury. Eur J Clin Microbiol Infect Dis. 2019; 39(4):723-728. DOI: 10.1007/s10096-019-03779-6. View

Soman R, Bakthavatchalam Y, Nadarajan A, Dwarakanathan H, Venkatasubramanian R, Veeraraghavan B . Is it time to move away from polymyxins?: evidence and alternatives. Eur J Clin Microbiol Infect Dis. 2020; 40(3):461-475. DOI: 10.1007/s10096-020-04053-w. View

Marsot A, Guilhaumou R, Riff C, Blin O . Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. Clin Pharmacokinet. 2016; 56(2):127-138. DOI: 10.1007/s40262-016-0428-x. View

Abdul-Aziz M, Alffenaar J, Bassetti M, Bracht H, Dimopoulos G, Marriott D . Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020; 46(6):1127-1153. PMC: 7223855. DOI: 10.1007/s00134-020-06050-1. View

Edwards M, Mythen M . Fluid therapy in critical illness. Extrem Physiol Med. 2014; 3:16. PMC: 4178546. DOI: 10.1186/2046-7648-3-16. View

Oparaoji E, Cornwell 3rd E, Hekmat E, Lum Cheong R, Adir J, Siram S . Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm. 1993; 12(2):131-4. View

Taccone F, Laterre P, Spapen H, Dugernier T, Delattre I, Layeux B . Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010; 14(2):R53. PMC: 2887170. DOI: 10.1186/cc8945. View

Marik P . Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993; 21(2):172-3. DOI: 10.1177/0310057X9302100206. View

10.

Garraffo R, Drugeon H, Dellamonica P, Bernard E, Lapalus P . Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother. 1990; 34(4):614-21. PMC: 171653. DOI: 10.1128/AAC.34.4.614. View

11.

Lanao J, Navarro A, Dominguez-Gil A, Tabernero J, RODRIGUEZ I, Gonzalez Lopez A . Amikacin concentrations in serum and blister fluid in healthy volunteers and in patients with renal impairment. J Antimicrob Chemother. 1983; 12(5):481-8. DOI: 10.1093/jac/12.5.481. View

12.

Delattre I, Musuamba F, Nyberg J, Taccone F, Laterre P, Verbeeck R . Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit. 2010; 32(6):749-56. DOI: 10.1097/FTD.0b013e3181f675c2. View

13.

De Winter S, van Hest R, Dreesen E, Annaert P, Wauters J, Meersseman W . Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis. Eur J Drug Metab Pharmacokinet. 2021; 46(5):653-663. DOI: 10.1007/s13318-021-00698-w. View

14.

Meraz-Munoz A, Langote A, Jhaveri K, Izzedine H, Gudsoorkar P . Acute Kidney Injury in the Patient with Cancer. Diagnostics (Basel). 2021; 11(4). PMC: 8065801. DOI: 10.3390/diagnostics11040611. View

15.

Bagshaw S, Laupland K, Doig C, Mortis G, Fick G, Mucenski M . Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care. 2005; 9(6):R700-9. PMC: 1414056. DOI: 10.1186/cc3879. View

16.

Benoit D, Hoste E . Acute kidney injury in critically ill patients with cancer. Crit Care Clin. 2009; 26(1):151-79. DOI: 10.1016/j.ccc.2009.09.002. View

17.

Lode H, Grunert K, Koeppe P, Langmaack H . Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis. 1976; 134 SUPPL:S316-22. DOI: 10.1093/infdis/135.supplement_2.s316. View

18.

Mahmoudi L, Mohammadpour A, Ahmadi A, Niknam R, Mojtahedzadeh M . Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci. 2013; 17(3):285-91. View

19.

Arechiga-Alvarado N, Medellin-Garibay S, Milan-Segovia R, Ortiz-Alvarez A, Magana-Aquino M, Romano-Moreno S . Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions. Antimicrob Agents Chemother. 2020; 64(5). PMC: 7179627. DOI: 10.1128/AAC.02178-19. View

20.

Holweger K, Lipp H, Dietz K, Hartmann J, Bokemeyer C . Novel algorithm for more accurate calculation of renal function in adults with cancer. Ann Pharmacother. 2008; 42(12):1749-57. DOI: 10.1345/aph.1L216. View